Skip to main content
Clinical Trials/NCT00892814
NCT00892814
Active, not recruiting
Not Applicable

Partial Breast Versus Whole Breast Irradiation to Women ≥ 60 Years Operated With Breast Conservation for Early Breast Cancer: a Randomized Fase II Trial

Danish Breast Cancer Cooperative Group1 site in 1 country882 target enrollmentMay 14, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Carcinoma
Sponsor
Danish Breast Cancer Cooperative Group
Enrollment
882
Locations
1
Primary Endpoint
Grade 2 and/or 3 fibrosis after radiotherapy
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

The purpose of this trial is to investigate the difference in late radiation morbidity between partial breast irradiation and whole breast irradiation given to women operated on with breast conservation surgery for early breast cancer with a low risk of local recurrence.

Detailed Description

The study is 2-armed. In both treatment arms the radiotherapy consists of 40 Gy in 15 fractions, 2.67 Gy per fraction. The primary endpoint in the trial is late radiation morbidity evaluated as fibrosis, secondary endpoints are other types of late morbidity, rate of local recurrence and an attempt to establish a genetic risk profile for development of late radiation morbidity. The hypothesis is that women operated with breast conservation for a breast carcinoma with low risk of local recurrence can be offered partial breast irradiation without risking more late radiation morbidity compared to whole breast irradiation.

Registry
clinicaltrials.gov
Start Date
May 14, 2009
End Date
March 2026
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Danish Breast Cancer Cooperative Group
Responsible Party
Principal Investigator
Principal Investigator

Birgitte Offersen

M.D., Ph.D., ass. professor

Danish Breast Cancer Cooperative Group

Eligibility Criteria

Inclusion Criteria

  • women 60 years or older
  • operated for unilateral, unifocal early breast cancer pT1, pN0, M0, grade I or II, positive estrogen and/or progesterone receptor, HER2 negative

Exclusion Criteria

  • lobular carcinoma

Outcomes

Primary Outcomes

Grade 2 and/or 3 fibrosis after radiotherapy

Time Frame: 3 years

Secondary Outcomes

  • Any other late morbidity after adjuvant radiotherapy, genetic risk profile for late morbidity, recurrence/survival(10 years)

Study Sites (1)

Loading locations...

Similar Trials